If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> ONCOLOGY<br /> EMJ Oncol. 2018 Suppl 1 • europeanmedical-journal.com<br /> INSIDE<br /> The Role of PARP Inhibitors<br /> in Ovarian Cancer:<br /> An Emerging Picture<br /> The Role of PARP Inhibitors in Ovarian Cancer:<br /> An Emerging Picture<br /> This satellite symposium took place on 10th September 2017<br /> as part of the European Society for Medical Oncology<br /> (ESMO) Congress in Madrid, Spain<br /> Chairpeople: Ana Oaknin1<br /> Speakers: Michael J. Birrer,2 Jonathan Ledermann,3 Iain McNeish,4<br /> Domenica Lorusso5<br /> 1. Vall d’Hebron University Hospital, Barcelona, Spain<br /> 2. University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham,<br /> Alabama, USA<br /> 3. UCL Cancer Institute, University College London, London, UK<br /> 4. Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, Universi<a title="EMJ Oncol. 2018 Suppl 1 page 1" href="http://viewer.zmags.com/publication/d911a339?page=1"> ONCOLOGY EMJ Oncol. 2018 Suppl 1 • europeanmedica</a> <a title="EMJ Oncol. 2018 Suppl 1 page 2" href="http://viewer.zmags.com/publication/d911a339?page=2"> The Role of PARP Inhibitors in Ovarian Cancer: </a> <a title="EMJ Oncol. 2018 Suppl 1 page 3" href="http://viewer.zmags.com/publication/d911a339?page=3"> Meeting Summary Dr Oaknin welcomed the delegates </a> <a title="EMJ Oncol. 2018 Suppl 1 page 4" href="http://viewer.zmags.com/publication/d911a339?page=4"> chemotherapy, and 80% of patients respond to</a> <a title="EMJ Oncol. 2018 Suppl 1 page 5" href="http://viewer.zmags.com/publication/d911a339?page=5"> grade ≥3 adverse event (AE) associated with bevac</a> <a title="EMJ Oncol. 2018 Suppl 1 page 6" href="http://viewer.zmags.com/publication/d911a339?page=6"> A second anti-angiogenic molecule, cediranib, has</a> <a title="EMJ Oncol. 2018 Suppl 1 page 7" href="http://viewer.zmags.com/publication/d911a339?page=7"> A second olaparib maintenance study, SOLO2,23 fur</a> <a title="EMJ Oncol. 2018 Suppl 1 page 8" href="http://viewer.zmags.com/publication/d911a339?page=8"> HRD (BRCA mut + BRCA wt/LOH high) Rucaparib n=236</a> <a title="EMJ Oncol. 2018 Suppl 1 page 9" href="http://viewer.zmags.com/publication/d911a339?page=9"> Finally, the Phase III trial of rucaparib, ARIEL3</a> <a title="EMJ Oncol. 2018 Suppl 1 page 10" href="http://viewer.zmags.com/publication/d911a339?page=10"> BRCA1 or BRCA2 germline mutations. Toxicity is ge</a> <a title="EMJ Oncol. 2018 Suppl 1 page 11" href="http://viewer.zmags.com/publication/d911a339?page=11"> BRCA wt Frequency of tumours LOH high LOH low B</a> <a title="EMJ Oncol. 2018 Suppl 1 page 12" href="http://viewer.zmags.com/publication/d911a339?page=12"> the treatment setting; assessing HRD may be inval</a> <a title="EMJ Oncol. 2018 Suppl 1 page 13" href="http://viewer.zmags.com/publication/d911a339?page=13"> with advanced ovarian cancer. The Phase I/II ANAN</a> <a title="EMJ Oncol. 2018 Suppl 1 page 14" href="http://viewer.zmags.com/publication/d911a339?page=14"> 2015;5(11):1137-54. 18. Konecny GE, Kristeleit </a> <a title="EMJ Oncol. 2018 Suppl 1 page 15" href="http://viewer.zmags.com/publication/d911a339?page=15"> maintenance therapy in subjects with newly diagno</a>